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860-1 The Design, Synthesis and Cardiorenal Actions of a 
New Chimeric Natriuretic Peptide CD-NP 
Ondrei Lisy, John C. Burnett, Jr., Mayo Clinic, Rochester, MN 
Background: C-type natriuretic peptide (CNP) is a 22.amino-acid (AA) peptide of endot- 
helial cell origin which is powerful venodilator but lacks renal adions. Dendroaspis natri- 
uretic peptide (DNP) is a recently discovered 38-AA peptide structurally similar to ANP, 
BNP and CNP with potent natriuretic and vasoactive actions. Data suggest that among 
natriurebc peptides DNP may be the most resistant to degradation by neutral endopepti- 
dase which may contribute to enhanced biological actions. 
Methods: Based upon such potent biological properties of both peptides, we designed, 
synthesized and assessed the cardiorenal actIons of a chimeric peptide CD-NP. which 
possesses the 22.AA core ring structure of CNP and the 15.AA linear C-terminus of 
DNP. We assessed the therapeutic potential of parenterally administered CD-NP upon 
cardiorenal and endocrine function in 6 normal anesthetized dogs. Intravenous CD-NP 
was infused after baseline measurements at 10, 50 and 100 ngikglmln. * ~~0.05 vs. 
baseline. 
Results: Administration of low, medium and high dose CD-NP decreased MAP (from 
baseline 137+6 to 13426 and 126+5 and 118*6* mmHg), RAP (from 1.0+0.3 to 0.5*0.4 
and -0.03iO.6’ and -0.4*0.6’ mmHg) and PCWP (from 6.4eO.4 to 5.2~0.5’ and 4.4iO.6’ 
and 3.6tO.5’ mmHg). These actions were associated with a decrease ln heart rate (from 
130+2 to 124+5 and 115*3’ and 11924 bpm). CD-NP increased GFR (from 37~3 lo 
3322 and 50+8 and 55+6’ mllmin), enhanced natriuresis (UNaV from 48+17 lo 123i23 
and 326+51’ and 462*69* pEqimin) and diuresis (UV from 0.7+0.2 to 1.7iO.3 and 
4.0+0.7* and 4.5+0.7’ ml/min) and activated cGMP in plasma (from 8.5~1.5 to 13.5-tl.6 
and 28.1*2.1* and 50.lr2.1’ pmollml) and urine. All three doses of CD-NP decreased 
plasma renin activity (from 8.2+1 to 5.9*1’ and 3.9kO.7’ and 6.3il .l’ nglmlihr). 
Conclusion: We repo;t the design, synthesis and cardiorenal actions of a new chimeric 
peptide CD-NP. which activates the cGMP pathway, reduces cardiac filling pressures. 
augments natriuresis and diuresis and possesses renin-suppressing properties. These 
findings support a possible therapeutic role for this new designer peptide in the treatment 
of cardiovascular diseases such as heart failure and hypertension. 
4:15 p.m. 
860-2 Angiotensin II Type 1 Receptor and Endothelin Type A 
Receptor Antagonists Prevent Ventricular Fibrosis in 
the Hypertensive Heart Through Different Mechanisms 
Junichl Yoshida, Kazuhlro Yamamoto, Toshiaki Mano, Yasushi Sakata, Nagahlro 
Nishikawa, Masatsugu Hod. Tohur Masuyama. Osaka University Graduate School of 
Medicine, Osaka, Japan 
Background: LV fibrosis contributes to the development of heart failure. Extracellular 
matrix (ECM) is regulated by its synthesis and degradation, and the balance between 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) 
mainly determlnes the degradation. Blockade of renin-angiotensin and endothalin sys- 
tems prevented the transition to overt heart failure in hypertensive hearts and their bene- 
ficial effects were accompanied wth inhibition of LV fibrosis. However, mechanisms how 
the antagonists exerl their effects on ECM regulatory system remain unclear. 
Methods: Dahl salt-sensitive rats (DSR) fed on 8% NaCl from 7wks were divided into 3 
groups: 6 untreated rats, 6 rats treated with subdepressor dose of anglotensin II type 1 
receptor antagonist (ARB), candesartan. since 8 wks, and 6 rats treated with subdepres- 
sor dose of endothelin type A receptor antagonist (ETB), TA-0201, since 8 wks. Six DSR 
fed on normal chow sewed as control. 
Result: Data at 13 wks are shown in the table. ARB and ETB similarly Inhibited fibrosis. 
ARB, not ETB, normalized collagen mRNA level. ETB suppressed gene expression of 
TIMP-2 without affecting that of MMP-2 and increased a ratio of MMP-2 lo TIMP-2 mRNA 
levels. ETB provided greater gelatinolytic activity as assessed with in vitro gelatin zymog- 
raphy than ARB, suggesting augmented collagen degradation in the rats treated with 
ETB. 
Conclusion: ARB and ETB inhibit ventricular fibrosis through different modulation of 
ECM regulatory system. 
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4:30 p.m. 
860-3 Comparison of Vasodilation by CVT-3146, a Novel A2, 
Receptor Agonist, and Adenosine in Different Vascular 
Beds in Awake Dogs 
Gona Zhao, Axel Linke, Xiaobin Xu, Manuel Ochoa, Francis Belloni, Luiz Belardinelli, 
Thoams Hintze, CV Therapeutics, Palo Alto, CA, New York Medical College, Valhalla, 
NY 
Background: We have previously shown in awake dogs that CVT-3146 (CVT) causes a 
smaller decrease in total peripheral resistance compared to adenosine (ADO), but it 
causes an equal or greater increase in coronary blood flow than ADO. In this study. we 
compared vasodilator effects of CVT to those of ADO in different vascular beds in awake 
dogs. 
Methods: Dogs were chronically instrumented for measurements of the blood flow in 
coronary (CBF), mesenteric (MBF), hindlimb (LBF), and renal (RBF) vascular beds, and 
hemodynamics. 
Resulta: Bolus injections (iv) of CVl (0.1 to 2.5pglkg) and ADO (10 to 250W/kg) caused 
significant increases in CBF (35+6 to 205*23% and 58+13 to 163*18%) and MBF (18~4 
to 88+14% and 36*8 to 84+5%). CVT is a more potent and longer lasting coronary 
vasodilator compared to ADO (the duration for CBF above P-fold of the baseline: CVT 
(2.5&kg): 130tl9s; ADO (250@kg): 16+3s, PcO.05). As shown in the figure 
(mean*SE. n=6), CVT caused a smaller increase in LBF than ADO. ADO caused a dose- 
dependent renal vasoconstriction (RBF -46*7 lo -85+4%), whereas CVT has no or a llttle 
effect on RBF (-522 to -11+4%, PcO.05, compared to ADO). 
Conclusion: CVT-3146 is a more selective and potent coronary vasodilator than ADO. 
CVT-3146 has no significant effect on renal blood flow in awake dogs. These features of 
CVT-3146 make it an ideal candidate for radionuclide myocardial perfusion imaging. 
4:45 pm. 
660-4 A New Perspective on the Pharmacological Treatment 
of Vagal Induced Atrial Fibrillation: Combined Inhibition 
of Muscarnic Potassium Current and IKr 
Bodo Brandt?, Marc Van Bracht, Rolf Borchard, lngo Wickenbrock, Daniel Dlrkmann, 
Magnus Prull, Nadme Bodanowski. Hans-Joachim Trappe, University of Bochum, Herne, 
Germany 
Background: Pharmacological treatment of atrial fibrillation (AF) is limited by Induction of 
malignant ventricular arrhythmias. Developing new drugs one promising strategy is a 
more specific treatment of the atria. Muscarinic potassium current (IK(ACh)) is predomi- 
nantly expressed in supraventricular tlssua. We studied the profile of representative class 
III drugs in respect to their effect on IK(ACh). 
Methods: In guinea-pig atrial myocytes IK(ACh) was activated by using acetylcholine 
